Titan Pharmaceuticals (de) P/E Ratio

Titan Pharmaceuticals (de) (TTNP) currently reports a P/E ratio of 1.23758917760141e+16. That is above the Healthcare sector average of 27.42. Use the charts on this page to explore Titan Pharmaceuticals (de)'s P/E ratio history and peer comparisons.

Titan Pharmaceuticals (de)'s P/E ratio of 1.23758917760141e+16 is higher than the Healthcare sector average of 27.42. That is roughly 4.512721472707016e+16% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Titan Pharmaceuticals (de)'s market price to a fundamental measure such as earnings, sales, or book value. At 1.23758917760141e+16, TTNP can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 1.23758917760141e+16, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for Titan Pharmaceuticals (de), and consider following TTNP for alerts when major investors trade the stock.

Titan Pharmaceuticals (de) is classified in the Healthcare sector. On P/E ratio, it currently shows 1.23758917760141e+16 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TTNP with unrelated industries.